Lemelin A, Maucort-Boulch D, Castel-Kremer E, et al. - Since the incidence of neuroendocrine tumors (NETs) is rising, particularly in elderly patients, researchers desired to know about the features, treatment pattern, and outcomes of metastatic NET patients. Consecutive metastatic NET patients (mNETs), diagnosed between January 1990 and December 2017, were included in the Lyon Real-life Evidence in Metastatic NeuroEndocrine Tumors study. Patients ≥ 70 years old (yo) were compared to patients < 70 yo. In total, 866 patients were involved, 198 were ≥ 70 yo. No significant difference was found in features except that elderly patients had more frequently synchronous metastasis. Patients ≥ 70 yo have worse survival, die frequently from their disease, and are undertreated in contrast to younger patients. The most common cause of death was associated with the progression of the disease.